This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

• HC Wainwright & Co. analyst Edward White downgraded the rating for Adicet Bio, Inc. ACET from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. See how other analysts view this stock.
• B of A Securities analyst Graham Perry downgraded Novartis AG NVS from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. See how other analysts view this stock.
• Piper Sandler analyst David Amsellem downgraded the rating for Supernus Pharmaceuticals, Inc. SUPN from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. See how other analysts view this stock.
• Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. ANIP from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. See how other analysts view this stock.

Considering buying NVS stock? Here’s what analysts think:

Read Next:

• Jim Cramer Says AES Is ‘Very Inexpensive’, Recommends Buying This Industrial Stock